{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:08:48Z","timestamp":1754093328768,"version":"3.41.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[1999,4]]},"DOI":"10.1023\/a:1018835516040","type":"journal-article","created":{"date-parts":[[2003,2,19]],"date-time":"2003-02-19T16:23:59Z","timestamp":1045671839000},"page":"575-583","source":"Crossref","is-referenced-by-count":9,"title":["Population Pharmacokinetics of Tirilazad: Effects of Weight, Gender, Concomitant Phenytoin, and Subarachnoid Hemorrhage"],"prefix":"10.1007","volume":"16","author":[{"given":"Joseph C.","family":"Fleishaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Fiedler-Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus H.","family":"Grasela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"303548_CR1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1358\/dof.1989.014.02.101095","volume":"14","author":"J. M. Braughler","year":"1989","unstructured":"J. M. Braughler, E. D. Hall, J. Jacobsen, J. M. McCall, and E. D. Means. The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future\n14:143\u2013152 (1989).","journal-title":"Drugs Future"},{"issue":"Suppl1","key":"303548_CR2","first-page":"S29","volume":"20","author":"N. F. Kassell, E. C. Haley, W. M. Alves, C. A. Hansen, B. Weir,the participants.","year":"1993","unstructured":"N. F. Kassell, E. C. Haley, W. M. Alves, C. A. Hansen, B. Weir, and the participants. Phase two trial of tirilazad in aneurysmal subarachnoid hemorrhage. Can. J. Neurol. Sci.\n20(Suppl 1):S29 (1993).","journal-title":"Can. J. Neurol. Sci."},{"key":"303548_CR3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3171\/jns.1996.84.2.0221","volume":"84","author":"N. F. Kassell, E. C. Haley, C. Apperson-Hansen, W. M. Alves,the participants.","year":"1996","unstructured":"N. F. Kassell, E. C. Haley, C. Apperson-Hansen, W. M. Alves, and the participants. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage; a cooperative study in Europe\/Australia\/New Zealand. J. Neurosurg.\n84:221\u2013228 (1996).","journal-title":"J. Neurosurg."},{"key":"303548_CR4","first-page":"223","volume":"32","author":"J. C. Fleishaker","year":"1994","unstructured":"J. C. Fleishaker, L. K. Hulst, and G. R. Peters. Multiple dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg\/kg\/day administered over 5\u201310 days in healthy volunteers. Int. J. Clin. Pharmacol. Ther.\n32:223\u2013230 (1994).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"303548_CR5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0022-3565(25)12957-1","volume":"277","author":"L. C. Wienkers","year":"1996","unstructured":"L. C. Wienkers, R. C. Steenwyk, P. E. Sanders, and P. G. Pearson. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J. Pharmacol. Exp. Ther.\n277:982\u2013990 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"303548_CR6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/clpt.1994.153","volume":"56","author":"J. C. Fleishaker","year":"1994","unstructured":"J. C. Fleishaker, L. K. Hulst, and G. R. Peters. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther\n56:389\u2013397 (1994).","journal-title":"Clin Pharmacol Ther"},{"key":"303548_CR7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jps.2600840305","volume":"84","author":"J. C. Fleishaker","year":"1995","unstructured":"J. C. Fleishaker, L. K. Pearson, and G. R. Peters. Phenytoin causes a rapid increase in 6\u03b2-hydroxycortisol urinary excretion in humans\u2014a putative measure of CYP3A induction. J. Pharm. Sci.\n84:292\u2013294 (1995).","journal-title":"J. Pharm. Sci."},{"key":"303548_CR8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002280050082","volume":"50","author":"J. C. Fleishaker","year":"1996","unstructured":"J. C. Fleishaker, L. K. Hulst-Pearson, and G. R. Peters. Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Eur. J. Clin. Pharmacol.\n50:139\u2013145 (1996).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"303548_CR9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0022-3565(25)12958-3","volume":"277","author":"J. C. Fleishaker","year":"1996","unstructured":"J. C. Fleishaker, P. G. Pearson, L. C. Wienkers, L. K. Pearson, and G. R. Peters. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J. Pharmacol. Exp. Ther.\n277:991\u2013998 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"303548_CR10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/clpt.1994.45","volume":"55","author":"L. K. Hulst","year":"1994","unstructured":"L. K. Hulst, J. C. Fleishaker, G. R. Peters, J. D. Harry, D. M. Wright, and P. Ward. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin. Pharmacol. Ther.\n55:378\u2013384 (1994).","journal-title":"Clin. Pharmacol. Ther."},{"key":"303548_CR11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00045391-199508000-00007","volume":"2","author":"J. C. Fleishaker","year":"1995","unstructured":"J. C. Fleishaker, L. K. Hulst-Pearson, and G. R. Peters. Effect of gender and menopausal status on the pharmacokinetics of tirilazad mesylate in healthy subjects. Am. J. Ther.\n2:553\u2013560 (1995).","journal-title":"Am. J. Ther."},{"key":"303548_CR12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/js960410e","volume":"86","author":"J. C. Fleishaker","year":"1997","unstructured":"J. C. Fleishaker, R. N. Straw, and C. J. Cross. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults. J. Pharm. Sci.\n86:434\u2013437 (1997).","journal-title":"J. Pharm. Sci."},{"key":"303548_CR13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3171\/jns.1997.86.3.0467","volume":"86","author":"E. C. Haley, N. F. Kassell, C. Apperson-Hansen, M. H. Maile, W. M. Alves,the participants.","year":"1997","unstructured":"E. C. Haley, N. F. Kassell, C. Apperson-Hansen, M. H. Maile, W. M. Alves, and the participants. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J. Neurosurg.\n86:467\u2013474 (1997).","journal-title":"J. Neurosurg."},{"key":"303548_CR14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/j.1552-4604.1993.tb03941.x","volume":"33","author":"J. C. Fleishaker","year":"1993","unstructured":"J. C. Fleishaker, G. R. Peters, K. S. Cathcart, and R. C. Steenwyk. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. J. Clin. Pharmacol.\n33:182\u2013190 (1993).","journal-title":"J. Clin. Pharmacol."},{"key":"303548_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/j.1552-4604.1993.tb03940.x","volume":"33","author":"J. C. Fleishaker","year":"1993","unstructured":"J. C. Fleishaker, G. R. Peters, and K. S. Cathcart. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. J. Clin. Pharmacol.\n33:175\u2013181 (1993).","journal-title":"J. Clin. Pharmacol."},{"key":"303548_CR16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/j.1552-4604.1994.tb02048.x","volume":"34","author":"J. C. Fleishaker","year":"1994","unstructured":"J. C. Fleishaker, L. K. Hulst, and G. R. Peters. Lack of a pharmacokinetic\/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. J. Clin. Pharmacol.\n34:837\u2013841 (1994).","journal-title":"J. Clin. Pharmacol."},{"key":"303548_CR17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1023\/A:1018988331700","volume":"11","author":"J. C. Fleishaker","year":"1994","unstructured":"J. C. Fleishaker, L. K. Hulst, and G. R. Peters. Lack of pharmacokinetic interaction between cimetidine and tirilazad mesylate. Pharm. Res.\n11:341\u2013344 (1994).","journal-title":"Pharm. Res."},{"issue":"Suppl1","key":"303548_CR18","first-page":"S334","volume":"10","author":"L. K. Hulst","year":"1993","unstructured":"L. K. Hulst, J. C. Fleishaker, and G. R. Peters. Single dose proportionality of tirilazad mesylate pharmacokinetics in healthy male volunteers. Pharm. Res.\n10(Suppl 1):S334 (1993).","journal-title":"Pharm. Res."},{"key":"303548_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002280050112","volume":"50","author":"L. K. Pearson","year":"1996","unstructured":"L. K. Pearson, J. C. Fleishaker, and G. R. Peters. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis. Eur. J. Clin. Pharmacol.\n50:299\u2013304 (1996).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"303548_CR20","first-page":"28","volume":"35","author":"J. C. Fleishaker","year":"1997","unstructured":"J. C. Fleishaker and G. R. Peters. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg\/kg\/day. Int. J. Clin. Pharmacol. Ther.\n35:28\u201332 (1997).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"volume-title":"NONMEM User's Guides","year":"1992","key":"303548_CR21","unstructured":"S. L. Beal and L. B. Sheiner, eds. NONMEM User's Guides, NONMEM Project Group, University of California at San Francisco, San Francisco, 1992."},{"key":"303548_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1099-081X(199803)19:2<91::AID-BDD78>3.0.CO;2-T","volume":"19","author":"J. C. Fleishaker","year":"1998","unstructured":"J. C. Fleishaker, L. K. Pearson, and G. R. Peters. Induction of tirilazad clearance by phenytoin. Biopharm. Drug. Disp.\n19:91\u201396 (1998).","journal-title":"Biopharm. Drug. Disp."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1018835516040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1018835516040\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1018835516040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:45:57Z","timestamp":1754034357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1018835516040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["303548"],"URL":"https:\/\/doi.org\/10.1023\/a:1018835516040","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}